1. Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects.
- Author
-
Meijer, Suzy E., Halutz, Ora, Adler, Amos, Levytskyi, Katya, Tau, Luba, Dekel, Michal, Cohen-Poradosu, Ronit, Katchman, Evgene, Shasha, David, Ablin, Jacob, Choshen, Guy, Jacob, Giris, Wasserman, Asaf, Ingbir, Merav, Cohen, Yael C., Perry, Chava, Ram, Ron, Herishanu, Yair, Bar On, Yael, and van Thijn, Elma
- Subjects
- *
COVID-19 treatment , *IMMUNOCOMPROMISED patients , *COVID-19 , *END of treatment , *PROGNOSIS - Abstract
In hemato-oncological patients, COVID-19 can present as a persistent infection with ongoing symptoms and viral replication over a prolonged period of time. Data are scarce on the preferred treatment options for these patients. We describe our experience with a five-day course of dual anti-viral treatment with remdesivir and nirmatrelvir/ritonavir for hemato-oncological immunocompromised patients with persistent COVID-19. Fifteen patients with a history of lymphoma, CLL, and MM were included. Eight were male, median age was 74. All patients had an immediate clinical and virological response. In 73 % of patients, PCR for SARS-CoV-2 became negative at the end of treatment and the rest had an increase in PCR cycle threshold (CT) values, with a median increase of 6 cycles. After a follow-up of three months, 60 % of patients remained in full clinical and virological remission. None required invasive mechanical ventilation or died. The side effects we observed, neutropenia, lactatemia and elevated transaminases, were mild and almost all transient in nature. We conclude that dual anti-viral treatment appears to be a valid treatment option for persistent COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF